Myriad Genetics, Inc. MYGN
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -2.63% | -3.16% | -0.28% | -1.56% | 0.21% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -2.63% | -3.16% | -0.28% | -1.56% | 0.21% |
| Cost of Revenue | 4.05% | 2.11% | -0.12% | -1.70% | -3.74% |
| Gross Profit | -5.44% | -5.37% | -0.34% | -1.50% | 1.97% |
| SG&A Expenses | 0.51% | -1.75% | -3.24% | -4.10% | -2.49% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.36% | -1.36% | -2.96% | -3.59% | -1.25% |
| Operating Income | -30.45% | -18.15% | 27.98% | 22.87% | 13.85% |
| Income Before Tax | 69.62% | 73.40% | -215.05% | -220.18% | -264.75% |
| Income Tax Expenses | 99.60% | 103.19% | 100.39% | -848.72% | -4,033.33% |
| Earnings from Continuing Operations | 67.77% | 71.51% | -294.38% | -187.43% | -245.26% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 67.77% | 71.51% | -294.38% | -187.43% | -245.26% |
| EBIT | -30.45% | -18.15% | 27.98% | 22.87% | 13.85% |
| EBITDA | -117.18% | -127.68% | 57.73% | 47.19% | 22.49% |
| EPS Basic | 68.56% | 72.02% | -286.80% | -181.58% | -233.51% |
| Normalized Basic EPS | -35.29% | -26.57% | 19.90% | 15.56% | 12.22% |
| EPS Diluted | 68.44% | 71.93% | -286.11% | -181.02% | -232.38% |
| Normalized Diluted EPS | -35.29% | -26.57% | 19.90% | 15.56% | 12.22% |
| Average Basic Shares Outstanding | 2.55% | 2.46% | 2.36% | 2.15% | 2.97% |
| Average Diluted Shares Outstanding | 2.55% | 2.46% | 2.36% | 2.15% | 2.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |